Breast cancer (BC) is the second most common and leading cause of mortality among women globally. Approximately 20% to 25% BC patients have amplification human epidermal growth factor receptor 2 (HER2) genes, a marker poor prognosis. However, introduction anti-HER2- therapies (trastuzumab, followed closely by lapatinib, pertuzumab, T-DM 1) has changed natural history HER2-positive improved prog...

We present a mathematical model to study the effects of HER2 over-expression on cell proliferation in breast cancer. The model illustrates the proliferative behavior of cells as a function of HER2 and EGFR receptors numbers, and the growth factor EGF. This mathematical model comprises kinetic equations describing the cell surface binding of EGF growth factor to EGFR and HER2 receptors, coupled ...

BACKGROUND We conducted this study to estimate the prevalence of biomarkers, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) among patients with breast cancer and to explore their effects on disease mortality. METHODS We conducted this registry-based retrospective cohort study in Tehran, in 2014, using the data on 1622 patients...

HER2+/ER+ breast cancer, a subset of the luminal B subtype, makes up approximately 10% of all breast cancers. The bidirectional crosstalk between HER2 and estrogen receptor (ER) in HER2+/ER+ breast cancer contributes to resistance towards both anti-estrogens and HER2-targeted therapies. TFF3 promotes breast cancer progression and has been implicated in anti-estrogen resistance in breast cancer....

The quality of chimeric antigen receptor (CAR)-T cell products, including the expression memory and exhaustion markers, has been shown to influence their long-term functionality. manufacturing process CAR-T cells should be optimized prevent early T during expansion. Activation by monoclonal antibodies is a critical step for expansion, which may sometimes induce excess stimulation cells. Given t...

Because metastatic breast cancer (MBC) is incurable in most cases, the goals of treatment are improvement in quality of life, management of symptoms, and prolonged survival. The human epidermal growth factor receptor 2 (HER2) is overexpressed in up to 30% of breast tumors, and before the development of HER-targeted therapy, HER2 positivity was predictive of poorer clinical outcomes. Trastuzumab...

Whereas the Her2/neu/erbB2 receptor (Her2) could be a molecular target of the receptor-positive breast cancer, the therapeutic targets of Her2-negative cancer largely remain to be established. The expression of Her2 was evaluated in 48 primary breast cancer tumors by immunohistochemistry. The identified Notch pathway was studied in genotoxin-dependent suppression of breast cancer-initiating cel...

Breast cancer is the most commonly diagnosed malignant tumor and leading cause of cancer-related death in women worldwide. Previous studies have demonstrated that patients with human epidermal growth factor receptor 2 (HER2)-positive/hormone (HR)-positive metastatic breast can benefit from HER2-targeted therapy. Pyrotinib, an irreversible tyrosine kinase inhibitor (TKI), has been to be effectiv...

The prognosis of breast cancer in pre-menopausal women is very variable and dependent on the interactions several biological factors. androgen receptor (AR) could be among prognostic variables related to survival although data scarce. aim study was examine relationship between expression outcomes estrogen (ER)-positive invasive carcinoma patients. We assessed AR ER-positive carcinomas correlate...

AIMS AND BACKGROUND To investigate the clinicopathological characteristics and prognosis of breast cancer subtypes classified by quantitative estrogen receptor (ER), progesterone receptor (PR), and Her2. METHODS AND STUDY DESIGN 923 patients with primary breast cancer having a median age of 53 years who were treated at the Cancer Hospital of Fudan University in Shanghai between January 2002 a...